Asia On The Move: Xian Janssen China President Thad Huston Leaves
This article was originally published in PharmAsia News
The change of seasons coincides with a flurry of key personnel moves in the Asian pharmaceutical scene. Xian Janssen China President Thad Huston moves up, Simcere vice president Jie Liu D’Elia joins BMS. Personnel changes also took place in Takeda, Lupin, inVentive Health and the Japan Pharmaceutical Manufacturers Association.
You may also be interested in...
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.